NeuroPace (NASDAQ:NPCE) Price Target Raised to $14.00 at JPMorgan Chase & Co.

NeuroPace (NASDAQ:NPCE – Get Free Report) had its price target increased by equities researchers at JPMorgan Chase & Co. from $9.00 to $14.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target points to a potential […]

Leave a Reply

Your email address will not be published.

Previous post comScore (NASDAQ:SCOR) Coverage Initiated at StockNews.com
Next post Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Consensus Recommendation of “Hold” from Brokerages